Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Overview of attention for article published in Blood, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 15 news outlets
blogs: 2 blogs
twitter: 51 X users

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 78 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 1 Bluesky users, with an upper bound of 569 followers.

Day 3 - revumenib in R/R NPM1m AML pubmed.ncbi.nlm.nih.gov/40332046/

results from the AUGMENT-101 study of revumenib in R/R NPM1m AML are out in @bloodjournal.bsky.social! - CR/CRh rate 23.4% & median duration 4.7 months -median OS 4 months; median OS 23 months in pts that achieved CR/CRh ashpublications.org/blood/arti…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.